Skip to content
CheckOrphan
  • Home
  • About Us
  • Log In
  • News
    • All News
    • Finance
    • Treatment
    • People
  • Videos
  • Treatments
  • Clinical Trials
  • Access Programs
    • About Access Programs
  • Diseases
  • Events
  • Networks
  • Research
Main Menu

Subscribe for Free Newsletter

Email *

Type *

Warning: foreach() argument must be of type array|object, null given in /var/www/wordpress/wp-content/themes/awaken-child/single-newsletter.php on line 54

* Required Field
Email Marketing Services by Benchmark

Generate RSS

  1. Home
  2. /
  3. Treatment
  4. /
  5. Acalabrutinib

Acalabrutinib

April 13, 2017
Acalabrutinib
Trade Name
Orphan Indication small lymphocytic lymphoma
EU Market Approval EU
EU Designation Date 2016-03-21 00:00:00
Sponsor Acerta Pharma, BV

Related Treatment

  • Autologous human peripheral blood Vdelta1+ T lymphocytes activated in
  • Autologous T cells transduced with retroviral vector encoding an anti-
  • Duvelisib
  • Monoclonal antibodies (murine or human) to B-cell lymphoma
  • Iodine I 131 Lym-1 Monoclonal Antibody
More Treatment
pw

About CheckOrphan

CheckOrphan is a non-profit organization located in Basel, Switzerland and Santa Cruz, California that is dedicated to rare, orphan and neglected diseases. CheckOrphan offers users an interactive and dynamic platform for all these diseases. This strategy allows visitors to be updated daily on all the latest news and interact with people internationally. This is essential, because due to the nature of these diseases, there is not a large concentration of individuals within any given proximity.
Click here to know more About Us

Your email is important to us

Each email is sent to a CheckOrphan staff member and will be answered. We only use a contact form to avoid spam.

    Copyright © 2023 CheckOrphan.
    Developed by: Gonza.io logo Developed by: WebOptimalSolutions Powered by: Cloudscale logo